Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Firefly Bio has raised $94.0M in total funding. The most recent round was Series A. The last funding was announced in February 2024.
Firefly Bio's investors include Eli Lilly, Versant Ventures, MPM Capital, Decheng Capital.
Firefly Bio is headquartered in San Francisco, United States.
Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Firefly Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Firefly Bio — Funding & Investors." VCBacked, February 15, 2024, https://www.vcbacked.co/company/firefly-bio. Accessed October 20, 2026.
VCBacked. (2024). Firefly Bio — Funding & Investors. Retrieved October 20, 2026, from https://www.vcbacked.co/company/firefly-bio
{{cite web |title=Firefly Bio — Funding & Investors |url=https://www.vcbacked.co/company/firefly-bio |website=VCBacked |access-date=October 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated